# ANCO's ASCO Highlights 2018 Breast Cancer Track



### Joshua Gruber, M.D., Ph.D

**Stanford University School of Medicine** 


## Adjuvant Tx Early Stage Breast Cancer


Abstract	Presenter	Title	
LBA1	Sparano	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor- positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.	Role of chemotherapy for intermediate recurrence score on Oncotype Dx.
503	Regan	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopaual women with hormone receptor- positive (HR+) and HER2-negative breast cancer (BC): Results from TEXT and SOFT.	8 year update on the role of ovarian suppression + Tam/AI in ER+ BC.
506	Earl	PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomized phase 3 non- inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.	Duration of therapy for adjuvant trastuzumab in HER2+ BC.


### **Metastatic Triple-Negative Breast Cancer**


Abstract	Presenter	Title		
1007	Schmid	AZD5363 plus Paclitaxel versus Placebo plus Paclitaxel as first-line therapy for metastatic triple- negative breast cancer ( <u>PAKT</u> ): A randomised, double-blind, placebo-controlled, phase II trial		Role of AKT inhibition in 1 <sup>st</sup> line metastatic TNBC?
			1	
















TAILORx Methods: Primary endpoints: • RS 11-25: IDFS • RS 0-10: DRFI	Endpoir	nts			
	Distant Recurrence	Local-Regional Recurrence	Contralateral Breast Cancer	Other Second Primary Cancer	Death
Invasive disease-free survival (IDFS)	Х	X	Х	Х	Х
Distant recurrence-free interval (DRFI)	Х				
Relapse-free interval (RFI)	×	Х			
Overall survival (OS)					Х
			Hudis et	al. J Clin Oncol 2007; 25	(15):2127-32
PRESENTED AT: 2018 ASCO ANNUAL MEETING #ASCO	8 reperty of the author, PRE level for reuse.	SENTED BY: JOSEPH A. Sparan	o, MD	EECOG-AC cancer research Reshaping the future of	group






















# TAILORx Take-Home points There are a large group of women for whom chemotherapy does not provide meaningful benefit: age > 50, ER+, LN-, Recurrence Score <26</li> Women < 50 may benefit from therapy beyond tamoxifen <ul> TAILORx provides evidence for chemotherapy benefit for RS > 15 Ovarian suppression +/- AI ??? Most benefit for RS 21-25 Chemotherapy should be considered for RS >25 across all groups This is an expansion from the old "high-risk" RS > 31









































































	Characteris	51105
	Paclitaxel + Capivasertib (N=68)	Paclitaxel + Placebo (N=70)
	55.2 (48.2 - 61.4)	51.9 (40.8 - 60.7)
0	43 (63.2)	48 (68.6)
1	24 (35.3)	22 (31.4)
2	1 (1.5)	0 (0.0)
<3	36 (52.9)	38 (54.3)
≥3	32 (47.1)	32 (45.7)
Yes	41 (60.3)	54 (77.1)
No	27 (39.7)	16 (22.9)
Liver	17 (25.0)	21 (30.0)
Lung	34 (50.0)	45 (64.3)
Bone	28 (41.2)	28 (40.0)
Lymph node/soft tissue	48 (70.6)	51 (72.9)
Yes	39 (57.4)	40 (57.1)
No	29 (42.6)	30 (42.9)
End ≤12 months	4 (5.9)	4 (5.7)
End >12 months	48 (70.6)	50 (71.4)
No prior chemotherapy	16 (23.5)	16 (22.9)
	1 2 <3 ≥3 Yes No Liver Lung Bone Lymph node/soft tissue Yes No End ≤12 months End >12 months	(N=68)           0         43 (63.2)           1         24 (35.3)           2         1 (1.5)           <3


	Paclitaxel + Capivasertib Paclitaxel + Placebo				00			
	(N=68)				(N=70)			
	All G	Grades	Grac	de 3/4	All G	irades	Gra	de 3/4
Number of patients with at least one AE	66	97.1%	-	-	64	91.4%	-	-
Diarrhoea	49	72.1%	9	13.2%	19	27.1%	1	1.4%
Fatigue		44.1%	3	4.4%	18	25.7%	0	-
Nausea	24	35.3%	1	1.5%	23	32.9%	0	-
Rash	28	41.2%	3	4.4%	11	15.7%	0	-
Neuropathy	17	25.0%	1	1.5%	13	18.6%	0	-
Stomatitis	18	26.5%	1	1.5%	10	14.3%	0	-
Infection	15	22.1%	3	4.4%	10	14.3%	1	1.4%
Decreased appetite	14	20.6%	0	-	8	11.4%	0	-
Alopecia	11	16.2%	0	-	9	12.9%	0	-
Vomiting	13	19.1%	1	1.5%	6	8.6%	1	1.4%
Constipation	5	7.4%	0	-	10	14.3%	0	-
Abdominal pain	7	10.3%	0	-	7	10.0%	0	-
Dry skin	10	14.7%	0	-	2	2.9%	0	-
Dyspnoea	6	8.8%	0	-	5	7.1%	0	-
Headache	8	11.8%	0	-	3	4.3%	0	-
Oedema	6	8.8%	0	-	4	5.7%	0	-
Dysgeusia	7	10.3%	0	-	3	4.3%	0	-
Joint pain	2	2.9%	0	-	6	8.6%	0	-
Neutropenia	6	8.8%	2	2.9%	2	2.9%	2	2.9%
Cough	1	1.5%	0	-	6	8.6%	0	-
Hyperglycaemia	6	8.8%	1	1.5%	1	1.4%	0	-











### **Take Home Message**

- PAKT trial showed that the addition of the AKT inhibitor capivasertib to 1<sup>st</sup> line paclitaxel in mTNBC prolonged PFS
  - Median PFS 5.9 vs 4.2 months in all patients; HR 0.74
  - Median PFS 9.3 vs 3.7 months in PIK3CA/AKT1/PTEN altered; HR 0.30
    - Alterations present in ~25% of study population
- Overall survival also improved
  - Median OS 19.1 vs 12.6 months in all patients; HR 0.61
  - Median OS NR vs 10.4 months in PIK3CA/AKT1/PTEN altered; HR 0.37
- Most common grade 3 or higher AEs were diarrhea, infection, neutropenia, rash and fatigue

